A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Neuroblastoma
A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
-
University of Alabama, Children's of Alabama, Birmingham, Alabama, United States,
Arkansas Children's Hospital, Little Rock, Arkansas, United States, 72202
UCSF Benioff Children's Hospital Oakland-, Oakland, California, United States,
Rady Children's Hospital, San Diego, California, United States, 92123
Connecticut Children's Hospital, Hartford, Connecticut, United States, 06106
Nicklaus Children's Miami, Miami, Florida, United States,
Arnold Palmer Hospital for Children, Orlando, Florida, United States, 32806
St. Joseph's Children's Hospital, Tampa, Florida, United States, 33614
Augusta University Health, Augusta, Georgia, United States,
Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States, 96813
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to 22 Years
ALL
No
Giselle Sholler,
Giselle Sholler, MD, STUDY_CHAIR, Beat Childhood Cancer
2035-09